DNA replication stress and emerging prospects for PARG inhibitors in ovarian cancer therapy
dc.contributor.author | Pillay, Nisha | |
dc.contributor.author | Brady, Rosie M | |
dc.contributor.author | Dey, Malini | |
dc.contributor.author | Morgan, Robert David | |
dc.contributor.author | Taylor, Stephen S | |
dc.date.accessioned | 2021-03-08T06:18:52Z | |
dc.date.available | 2021-03-08T06:18:52Z | |
dc.date.issued | 2021 | en |
dc.identifier.citation | Pillay N, Brady RM, Dey M, Morgan RD, Taylor SS. DNA replication stress and emerging prospects for PARG inhibitors in ovarian cancer therapy. Prog Biophys Mol Biol. 2021. | en |
dc.identifier.pmid | 33524442 | en |
dc.identifier.doi | 10.1016/j.pbiomolbio.2021.01.004 | en |
dc.identifier.uri | http://hdl.handle.net/10541/623811 | |
dc.description.abstract | Poly (ADP-ribosyl)ation has central functions in maintaining genome stability, including facilitating DNA replication and repair. In cancer cells these processes are frequently disrupted, and thus interfering with poly (ADP-ribosyl)ation can exacerbate inherent genome instability and induce selective cytotoxicity. Indeed, inhibitors of poly (ADP-ribose) polymerase (PARP) are having a major clinical impact in treating women with BRCA-mutant ovarian cancer, based on a defect in homologous recombination. However, only around half of ovarian cancers harbour defects in homologous recombination, and most sensitive tumours eventually acquire PARP inhibitor resistance with treatment. Thus, there is a pressing need to develop alternative treatment strategies to target tumours with both inherent and acquired resistance to PARP inhibition. Several novel inhibitors of poly (ADP-ribose)glycohydrolase (PARG) have been described, with promising anti-cancer activity in vitro that is distinct from PARP inhibitors. Here we discuss, the role of poly (ADP-ribosyl)ation in genome stability, and the potential for PARG inhibitors as a complementary strategy to PARP inhibitors in the treatment of ovarian cancer. | en |
dc.language.iso | en | en |
dc.relation.url | https://dx.doi.org/10.1016/j.pbiomolbio.2021.01.004 | en |
dc.title | DNA replication stress and emerging prospects for PARG inhibitors in ovarian cancer therapy | en |
dc.type | Article | en |
dc.contributor.department | Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK | en |
dc.identifier.journal | Progress in Biophysics and Molecular Biology | en |
dc.description.note | en] |